(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Canopy Growth, Rockwell Medical, and Rubicon Technology.

The three biggest losers today are Tattooed Chef, Aspen Group, and Signature Bank.

Winners today

1. Canopy Growth (CGC) – 52.1%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth rising 52.1% to $0.59 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Canopy growth (cgc) improves liquidity with another selloffAs a result, Canopy Growth is now better positioned to achieve its goal of becoming an asset-light, North America-focused cannabis business., As the cannabis industry continues to evolve, Canopy Growth remains committed to delivering innovative products that enhance the lives of consumers while creating sustainable value for shareholders.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-4.9.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -151.11%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 96.3% and 62.9%, respectively.

Volume

Today’s last reported volume for Canopy Growth is 86581100 which is 773.83% above its average volume of 9908200.

Sales Growth

Canopy Growth’s sales growth is negative 16.8% for the ongoing quarter and negative 14.9% for the next.

More news about Canopy Growth.

2. Rockwell Medical (RMTI) – 20%

Rockwell Medical, Inc., together with its subsidiaries, operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores. It also manufactures, sells, delivers, and distributes hemodialysis concentrates, such as CitraPure citric acid concentrate, Dri-Sate dry acid concentrate, RenalPure liquid acid concentrate, dry acid concentrate mixer, and RenalPure and SteriLyte powder bicarbonate concentrate; and ancillary products, including blood tubing, fistula needles, dialyzers, drugs, specialized component kits, dressings, cleaning agents, filtration salts, and other supplies used by hemodialysis providers. The company's dialysis concentrate products are used to maintain human life by removing toxins and replacing critical nutrients in the dialysis patient's bloodstream. It is also developing other therapeutic product candidates for the treatment of hospitalized patients with acute heart failure; and home infusion therapy that allows patients to receive intravenous medications at home. Its target customers include medium and small sized dialysis chains and independent dialysis centers. Rockwell Medical, Inc. was incorporated in 1996 and is headquartered in Wixom, Michigan.

NASDAQ ended the session with Rockwell Medical rising 20% to $5.46 on Monday, after four successive sessions in a row of gains. NASDAQ rose 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat positive trend exchanging session today.

Earnings Per Share

As for profitability, Rockwell Medical has a trailing twelve months EPS of $-1.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -343.04%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Rockwell Medical’s EBITDA is -14.62.

More news about Rockwell Medical.

3. Rubicon Technology (RBCN) – 14.96%

Rubicon Technology, Inc. provides monocrystalline sapphire for applications in optical and industrial systems in North America and Asia. The company offers optical and industrial sapphire products in various shapes and sizes, including round and rectangular windows and wafers, domes, tubes, and rods for a range of end markets comprising defense and aerospace, specialty lighting, instrumentation, sensors and detectors, semiconductor process equipment, electronic substrates, medical, and laser applications. It serves defense subcontractors, industrial manufacturers, fabricators, and resellers. The company was incorporated in 2001 and is based in Bensenville, Illinois.

NASDAQ ended the session with Rubicon Technology rising 14.96% to $1.44 on Monday, following the last session’s upward trend. NASDAQ rose 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Rubicon Technology has a trailing twelve months EPS of $0.07.

PE Ratio

Rubicon Technology has a trailing twelve months price to earnings ratio of 20.53. Meaning, the purchaser of the share is investing $20.53 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.64%.

Yearly Top and Bottom Value

Rubicon Technology’s stock is valued at $1.44 at 17:32 EST, way under its 52-week high of $17.74 and way higher than its 52-week low of $1.15.

More news about Rubicon Technology.

4. Riot Blockchain (RIOT) – 12.94%

Riot Platforms, Inc., together with its subsidiaries, operates as a bitcoin mining company in North America. It operates through Bitcoin Mining, Data Center Hosting, and Engineering segments. The company also provides co-location services for institutional-scale bitcoin mining companies; and critical infrastructure and workforce for institutional-scale miners to deploy and operate their miners. In addition, it engages in the design and manufacturing of power distribution equipment and custom engineered electrical products; electricity distribution product design, manufacture, and installation services primarily focused on large-scale commercial and governmental customers, as well as a range of markets, including data center, power generation, utility, water, industrial, and alternative energy; operation of data centers; and maintenance/management of computing capacity. The company was formerly known as Riot Blockchain, Inc. Riot Platforms, Inc. was incorporated in 1998 and is based in Castle Rock, Colorado.

NASDAQ ended the session with Riot Blockchain jumping 12.94% to $13.35 on Monday, after two sequential sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Riot Blockchain has a trailing twelve months EPS of $-4.29.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -48.54%.

Sales Growth

Riot Blockchain’s sales growth is 19.5% for the current quarter and 70.8% for the next.

More news about Riot Blockchain.

5. Coinbase (COIN) – 11.71%

Coinbase Global, Inc. provides financial infrastructure and technology for the cryptoeconomy in the United States and internationally. It offers the primary financial account in the cryptoeconomy for consumers; a marketplace with a pool of liquidity for transacting in crypto assets for institutions; and technology and services that enable developers to build crypto-based applications and securely accept crypto assets as payment. The company was founded in 2012 and is based in Wilmington, Delaware.

NASDAQ ended the session with Coinbase rising 11.71% to $79.93 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Coinbase has a trailing twelve months EPS of $-11.5.

Volume

Today’s last reported volume for Coinbase is 19623700 which is 29.98% above its average volume of 15096400.

More news about Coinbase.

6. Marathon (MARA) – 10.53%

Marathon Digital Holdings, Inc. operates as a digital asset technology company that mines digital assets with a focus on the blockchain ecosystem and the generation of digital assets in United States. The company was formerly known as Marathon Patent Group, Inc. and changed its name to Marathon Digital Holdings, Inc. in February 2021. Marathon Digital Holdings, Inc. was incorporated in 2010 and is headquartered in Fort Lauderdale, Florida.

NASDAQ ended the session with Marathon jumping 10.53% to $15.32 on Monday, after two consecutive sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Marathon has a trailing twelve months EPS of $-6.3.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -103.2%.

More news about Marathon.

7. MicroStrategy (MSTR) – 10.34%

MicroStrategy Incorporated provides enterprise analytics software and services in the United States, Canada, Europe, the Middle East, Africa, and internationally. It offers MicroStrategy, an enterprise analytics software platform that enables users to create visualizations, customize apps, and embed analytics directly into workflows; and MicroStrategy Cloud Environment, a managed software-as-a-service solution, which offers always-on threat monitoring and enables rapid analytics development and deployment to deliver security and data privacy requirements. The company also provides MicroStrategy Support that helps customers to achieve their system availability and uptime goals, and to improve the overall experience through highly responsive troubleshooting and proactive technical product support. In addition, it offers MicroStrategy Consulting, which offers customers with architecture and implementation services to help them quickly realize results, as well as helps to achieve returns on investment derived from understanding of data; and MicroStrategy Education that provides free and paid learning options, as well as holds and acquires bitcoin. The company offers its services through enterprise sales force and channel partners. It serves companies from a range of industries, including banking, technology, consulting, manufacturing, insurance, healthcare, and telecommunications, as well as the public sector. The company was incorporated in 1989 and is headquartered in Tysons Corner, Virginia.

NASDAQ ended the session with MicroStrategy rising 10.34% to $377.84 on Monday, after four consecutive sessions in a row of gains. NASDAQ rose 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, MicroStrategy has a trailing twelve months EPS of $-85.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -134.41%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

MicroStrategy’s EBITDA is 234.79.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MicroStrategy’s stock is considered to be oversold (<=20).

More news about MicroStrategy.

8. Tarena International (TEDU) – 8.75%

Tarena International, Inc., through its subsidiaries, provides professional education services through full-time and part-time classes under the Tarena brand in the People's Republic of China. It operates through two segments, Adult Training and Kid Training. The company offers education courses in 7 information technology (IT) subjects, such as Java, software testing, Linux and network engineering, Big Data, Web front-end development, Python, and network engineer courses; and 3 non-IT subjects, including digital art, online sales and marketing, computer-based design courses through live distance instruction, and visual effects-VFX, as well as classroom-based tutoring and online learning modules. It also provides 7 K-12 education programs for children, including computer coding and robotics programming courses under the TongchengTongmei brand. In addition, the company offers online learning platform for education courses and job placement training courses. As of December 31, 2020, it had a network of 104 directly managed learning centers in 45 cities; and 236 TongchengTongmei standalone learning centers in 53 cities. The company was founded in 2002 and is headquartered in Beijing, the People's Republic of China.

NASDAQ ended the session with Tarena International rising 8.75% to $2.61 on Monday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Tarena International has a trailing twelve months EPS of $0.03.

PE Ratio

Tarena International has a trailing twelve months price to earnings ratio of 87. Meaning, the purchaser of the share is investing $87 for every dollar of annual earnings.

Yearly Top and Bottom Value

Tarena International’s stock is valued at $2.61 at 17:32 EST, way under its 52-week high of $8.25 and higher than its 52-week low of $2.41.

Volume

Today’s last reported volume for Tarena International is 2091 which is 82.85% below its average volume of 12193.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Tarena International’s EBITDA is -0.74.

More news about Tarena International.

9. Aurora Cannabis (ACB) – 8.51%

Aurora Cannabis Inc., together with its subsidiaries, produces, distributes, and sells cannabis and cannabis-derivative products in Canada and internationally. It operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company produces, distributes, and sells medical and consumer cannabis products in Canada. It is also involved in the distribution of wholesale medical cannabis in the European Union (EU); distribution of wholesale medical cannabis in various international markets, including Australia, the Caribbean, South America, and Israel; supply of propagated vegetables and ornamental plants in North America; and distribution and sale of hemp-derived cannabidiol (CBD) products. In addition, the company cultivates and sells dried cannabis, cannabis oils, capsules, edible cannabis, cannabis extracts, and soft gels, which are ingested in various ways, including smoking, vaporizing, and consumption in the form of oil, capsules, edibles, and extracts; and provides dried flowers, vapes, dried milled strains, strain-specific extracts, strain specific cannabis oils, and concentrates. Further, it offers recreational cannabis products, such as flowers, vapes, ingestibles, concentrates, extracts, and CBD products; and patient counseling and outreach services. The company's adult-use brand portfolio includes Aurora Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard, as well as CBD brands, Reliva and KG7; and medical cannabis brands include MedReleaf, CanniMed, Aurora, Whistler Medical Marijuana Co, Pedanios, Bidiol, and CraftPlant. Aurora Cannabis Inc. is headquartered in Leduc, Canada.

NYSE ended the session with Aurora Cannabis rising 8.51% to $0.58 on Monday while NYSE rose 0.27% to $15,918.50.

Earnings Per Share

As for profitability, Aurora Cannabis has a trailing twelve months EPS of $-5.91.

Volatility

Aurora Cannabis’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.25%, a positive 0.19%, and a positive 2.94%.

Aurora Cannabis’s highest amplitude of average volatility was 1.04% (last week), 3.35% (last month), and 2.94% (last quarter).

More news about Aurora Cannabis.

10. Tilray (TLRY) – 8.33%

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

NASDAQ ended the session with Tilray rising 8.33% to $1.69 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Tilray has a trailing twelve months EPS of $-3.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -44.15%.

Yearly Top and Bottom Value

Tilray’s stock is valued at $1.69 at 17:32 EST, way under its 52-week low of $2.17.

More news about Tilray.

Losers Today

1. Tattooed Chef (TTCF) – -46.79%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, wood fire crusted pizza, handheld burritos, and bars and quesadillas. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores, as well as online. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef sliding 46.79% to $0.29 on Monday, after four consecutive sessions in a row of gains. NASDAQ jumped 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.7.

Volume

Today’s last reported volume for Tattooed Chef is 7595250 which is 542.24% above its average volume of 1182600.

More news about Tattooed Chef.

2. Aspen Group (ASPU) – -13.33%

Aspen Group, Inc., an education technology company, provides online higher education services in the United States. The company offers baccalaureate, master's, and doctoral degree programs in nursing and health sciences, business and technology, arts and sciences, and education fields through Aspen University and United States University. As of April 30, 2022, it had 13,334 degree-seeking students enrolled. Aspen Group, Inc. was founded in 1987 and is based in New York, New York.

NASDAQ ended the session with Aspen Group falling 13.33% to $0.13 on Monday, after two successive sessions in a row of losses. NASDAQ jumped 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Aspen Group has a trailing twelve months EPS of $-0.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -24.26%.

Sales Growth

Aspen Group’s sales growth is negative 24% for the ongoing quarter and negative 29.3% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Aspen Group’s stock is considered to be overbought (>=80).

Volume

Today’s last reported volume for Aspen Group is 355634 which is 382.74% above its average volume of 73669.

More news about Aspen Group.

3. Signature Bank (SBNY) – -12.5%

Signature Bank provides commercial banking products and services. It accepts various deposit products, including checking accounts, money market accounts, escrow deposit accounts, cash concentration accounts, certificates of deposit, and other cash management products. The company provides various lending products comprising commercial and industrial loans, real estate loans, and letters of credit. In addition, it offers asset management and investment products; and retirement products, such as individual retirement accounts and administrative services for retirement vehicles. Further, the company provides wealth management services to its high net worth personal clients; and purchases, sells, and assembles small business administration loans and pools. Additionally, it offers individual and group insurance products, including health, life, disability, and long-term care insurance products for business and private clients. As of December 31, 2021, the company operated 37 private client offices located in the metropolitan New York area, Connecticut, California, and North Carolina. Signature Bank was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with Signature Bank falling 12.5% to $0.21 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Signature Bank has a trailing twelve months EPS of $20.76.

PE Ratio

Signature Bank has a trailing twelve months price to earnings ratio of 0.01. Meaning, the purchaser of the share is investing $0.01 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 16.87%.

Moving Average

Signature Bank’s worth is way higher than its 50-day moving average of $0.13 and way under its 200-day moving average of $83.37.

More news about Signature Bank.

4. Technical Communications Corporation (TCCO) – -10.11%

Technical Communications Corporation engages in the design, development, manufacture, distribution, marketing, and sale of communications security devices, systems, and services worldwide. The company primarily provides data, video, fax, and voice networks. Its products include government systems, such as CSD 3324 SE secure telephone, fax and data system; CSD 3324 SP telephone and fax system; DSD 72A-SP military bulk ciphering system; and DSP 9000 radio encryption system, as well as the HSE 6000 squad radio headset and telephone encryptor for public safety special operations, land mobile radio applications, and for military applications. The company also provides network security systems comprising network encryption systems with centralized key and device management for IP, SONET/SDH, and frame relay networks to secure data in transit from local area network to local area network and across wide area networks. In addition, it offers secure office systems, such as CSD 4100 executive secure telephone and CipherTalk 8500 Internet protocol (IP)-based secure wireless phone. The company's products are used to protect confidentiality in communications between radios, landline telephones, mobile phones, facsimile machines, data network equipment over wires, fiber optic cables, radio waves, and microwave and satellite links. Further, it offers funded research and development, and technology development services. The company serves various markets, including foreign and domestic governmental agencies, law enforcement and military agencies, telecommunications carriers, financial institutions, and multinational companies requiring protection of mission-critical information. It sells directly to customers, original equipment manufacturers, and value-added resellers using its in-house sales force, as well as domestic and international representatives, consultants, and distributors. Technical Communications Corporation was founded in 1961 and is based in Concord, Massachusetts.

NASDAQ ended the session with Technical Communications Corporation falling 10.11% to $0.80 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Technical Communications Corporation has a trailing twelve months EPS of $-1.45.

Volume

Today’s last reported volume for Technical Communications Corporation is 1002 which is 64.53% above its average volume of 609.

Revenue Growth

Year-on-year quarterly revenue growth declined by 95.1%, now sitting on 464.66k for the twelve trailing months.

Moving Average

Technical Communications Corporation’s worth is way below its 50-day moving average of $0.90 and under its 200-day moving average of $0.88.

Yearly Top and Bottom Value

Technical Communications Corporation’s stock is valued at $0.80 at 17:32 EST, way under its 52-week high of $1.40 and way higher than its 52-week low of $0.40.

More news about Technical Communications Corporation.

5. Astrazeneca (AZN) – -8.83%

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc, as well as research collaboration with Sernova Corp. to evaluate novel potential therapeutic cell applications; and collaboration with Cholesgen (Shanghai) Co.Ltd. to advance research and development in hypercholesterolemia and related metabolic diseases. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

NYSE ended the session with Astrazeneca sliding 8.83% to $65.25 on Monday, following the last session’s upward trend. NYSE rose 0.27% to $15,918.50, after two consecutive sessions in a row of gains, on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Astrazeneca has a trailing twelve months EPS of $1.53.

PE Ratio

Astrazeneca has a trailing twelve months price to earnings ratio of 42.65. Meaning, the purchaser of the share is investing $42.65 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 13.05%.

Dividend Yield

As claimed by Morningstar, Inc., the next dividend payment is on Feb 22, 2023, the estimated forward annual dividend rate is 1.45 and the estimated forward annual dividend yield is 2.04%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 12.8% and 11.9%, respectively.

Sales Growth

Astrazeneca’s sales growth is 5.1% for the present quarter and 7.5% for the next.

Volatility

Astrazeneca’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.06%, a negative 0.08%, and a positive 0.85%.

Astrazeneca’s highest amplitude of average volatility was 0.57% (last week), 0.91% (last month), and 0.85% (last quarter).

More news about Astrazeneca.

6. BlackBerry (BB) – -5.24%

NYSE ended the session with BlackBerry sliding 5.24% to $5.24 on Monday while NYSE jumped 0.27% to $15,918.50.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BlackBerry’s stock is considered to be oversold (<=20).

Volatility

BlackBerry’s last week, last month’s, and last quarter’s current intraday variation average was 3.75%, 0.23%, and 2.15%.

BlackBerry’s highest amplitude of average volatility was 4.15% (last week), 2.11% (last month), and 2.15% (last quarter).

Volume

Today’s last reported volume for BlackBerry is 5873660 which is 23.04% above its average volume of 4773690.

More news about BlackBerry.

7. Smith & Nephew (SNN) – -5.12%

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. The company operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products, including instruments, technologies, and implants to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

NYSE ended the session with Smith & Nephew falling 5.12% to $30.60 on Monday while NYSE jumped 0.27% to $15,918.50.

Earnings Per Share

As for profitability, Smith & Nephew has a trailing twelve months EPS of $0.51.

PE Ratio

Smith & Nephew has a trailing twelve months price to earnings ratio of 60. Meaning, the purchaser of the share is investing $60 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.12%.

Dividend Yield

According to Morningstar, Inc., the next dividend payment is on Mar 29, 2023, the estimated forward annual dividend rate is 0.75 and the estimated forward annual dividend yield is 2.39%.

Moving Average

Smith & Nephew’s value is under its 50-day moving average of $31.36 and above its 200-day moving average of $27.83.

More news about Smith & Nephew.

8. Catalyst Pharmaceuticals (CPRX) – -5.06%

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.

NASDAQ ended the session with Catalyst Pharmaceuticals dropping 5.06% to $12.76 on Monday while NASDAQ jumped 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Catalyst Pharmaceuticals has a trailing twelve months EPS of $0.89.

PE Ratio

Catalyst Pharmaceuticals has a trailing twelve months price to earnings ratio of 14.34. Meaning, the purchaser of the share is investing $14.34 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 35.89%.

Volume

Today’s last reported volume for Catalyst Pharmaceuticals is 1245260 which is 38.08% below its average volume of 2011130.

More news about Catalyst Pharmaceuticals.

9. Viking Therapeutics (VKTX) – -4.75%

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

NASDAQ ended the session with Viking Therapeutics sliding 4.75% to $15.44 on Monday while NASDAQ rose 0.21% to $13,816.77.

Earnings Per Share

As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.77.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.71%.

Volume

Today’s last reported volume for Viking Therapeutics is 1557750 which is 56.77% below its average volume of 3604200.

Yearly Top and Bottom Value

Viking Therapeutics’s stock is valued at $15.44 at 17:32 EST, way below its 52-week high of $25.72 and way above its 52-week low of $2.54.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be oversold (<=20).

Earnings Before Interest, Taxes, Depreciation, and Amortization

Viking Therapeutics’s EBITDA is -56.81.

More news about Viking Therapeutics.

10. Reading International (RDIB) – -4.75%

Reading International, Inc., together with its subsidiaries, focuses on the ownership, development, and operation of entertainment and real property assets in the United States, Australia, and New Zealand. The company operates in two segments, Cinema Exhibition and Real Estate. The Cinema Exhibition segment operates multiplex cinemas. This segment operates its cinema exhibition businesses under the Reading Cinemas, Angelika Film Center, Consolidated Theatres, State Cinema, Event Cinemas, and Rialto Cinemas brands. The Real Estate segment develops, rents, or licenses retail, commercial, and live theater assets. As of December 31, 2020, the company had interests in 63 cinemas comprising approximately 515 screens; fee interests in two live theaters; fee interest in 44 Union Square property; fee interest in one cinema in Manhattan; fee interests in two cinemas in Australia and three cinemas in New Zealand; fee interest in entertainment-themed centers; fee interest in 2 office buildings; and fee ownership of approximately 8.9 million square feet of developed and undeveloped real estate assets. Reading International, Inc. was incorporated in 1999 and is headquartered in New York, New York.

NASDAQ ended the session with Reading International sliding 4.75% to $23.05 on Monday, after two sequential sessions in a row of losses. NASDAQ rose 0.21% to $13,816.77, following the last session’s upward trend on what was a somewhat bullish trend exchanging session today.

Earnings Per Share

As for profitability, Reading International has a trailing twelve months EPS of $-1.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.04%.

More news about Reading International.

Stay up to date with our winners and losers daily report